S1P receptor modulators
New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC
The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...
NOVEMBER 26, 2024
The ABCs of Optimizing Drug Sequencing for IBD
The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...
OCTOBER 13, 2024
Amiselimod Shows Promise for Mild to Moderate UC in Phase 2 Study
The investigational oral drug amiselimod outperformed placebo at controlling mild to moderate UC symptoms with no ...
OCTOBER 9, 2024
FDA Approves S1P Receptor Modulator for Moderate to Severe UC
The FDA has approved etrasimod (Velsipity, Pfizer), a selective sphingosine-1-phosphate receptor modulator, for ...
OCTOBER 13, 2023
Meta-Analysis Shows Efficacy of Advanced Orals in IBD
Treatment with a JAK inhibitor or S1P modulator increased remission in patients with UC, and JAK inhibitors are ...
MARCH 7, 2023
